A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 - Trial NCT05844228
Access comprehensive clinical trial information for NCT05844228 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vir Biotechnology, Inc. and is currently Not yet recruiting. The study focuses on Renal Impairment. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vir Biotechnology, Inc.
Timeline & Enrollment
Phase 1
Jun 01, 2023
Nov 24, 2024
Primary Outcome
Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and its metabolite AS(N-1)3'VIR-2218,Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and metabolite AS(N-1)3'VIR-2218,Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 metabolite AS(N-1)3'VIR-2218,%fe for VIR-2218 and its metabolite AS(N-1)3'VIR-2218,Ae for VIR-2218 and its metabolite AS(N-1)3'VIR-2218,CLr for VIR-2218 and its metabolite AS(N-1)3'VIR-2218
Summary
The rationale of this study is to evaluate the impact of renal function on the PK, safety,
 and tolerability of VIR-2218 in participants with normal renal function and participants with
 varying degrees of renal dysfunction who are otherwise medically stable
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05844228
Non-Device Trial